Productos Medix seeking entry into Europe and South American expansion
Productos Medix busca entrada en Europa y expansión en Sudamérica
Intel ID : 246026
| Synopsis |
|
Productos Medix, a Mexico City-based company engaged in the marketing of drugs to treat obesity, is seeking to foray into the European market, beginning with its entry into Spain, reported El Financiero on 13 March 2017, citing Productos Medix Managing Director Carlos López Patán. The company is also planning to launch operations in Ecuador, Chile, and Paraguay in 2017, as well as strengthening its operations in Argentina and Brazil. Productos Medix closes 2016 with a revenue of MXN 1.73bn, a 7% increase compared to 2015.
(content in spanish)
Productos Medix, comercializadora de medicamentos para el tratamiento de la obesidad con sede en la Ciudad de México, busca incursionar en el mercado europeo y comenzará con su entrada en España, ha publicado El Financiero el 12 de marzo de 2017, citando al director general de la empresa, Carlos López Patán. La empresa también planea comenzar a operar en Ecuador, Chile y Paraguay en 2017, además de consolidar sus operaciones en Argentina y Brasil. Productos Medix ha cerrado el 2016 con ingresos de MXN 1.730m, 7% más que en 2015. |
| Intel ID | 246026 | |
| Value | ND | |
| Native Currency | Euro (EUR) | |
|
Financial Data - Productos Medix
(31 Dec 2011) |
Revenue: EUR 42,12m Exchange Rate: 
|
|
| Date |
 |
|
| Country | |
|
| Region | ||
| Continent | |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.